The Life Sciences team advised Cugene in its exclusive worldwide license option agreement with AbbVie for CUG252, a potential best-in-class Treg-selective IL-2 mutein, as well as other novel IL-2 muteins, for the potential treatment of autoimmune and inflammatory diseases.
Cugene is a clinical-stage biotechnology company focused on developing next-generation precision immunology and oncology medicines to treat autoimmune disease and cancer.
Under the terms of the agreement, Cugene will receive an upfront payment of $48.5 million, and will also be eligible to receive development and regulatory milestones and a license option exercise payment if AbbVie exercises the option.
The Goodwin team was led by Wenseng “Wendy” Pan and consisted of Kevin Guan, Jin Paul, Daniel Karelitz, and Kirby Lewis.
For more details, read the press release and article in Endpoints.